Publications by authors named "Gwyn Saylor"
Article Synopsis
- The text discusses the importance of a multi-organizational data quality assessment (DQA) process that evaluates data consistency across different organizations and enhances traditional reliability methods.
- The Data Coordinating Center for Kaiser Permanente's research employs a standardized DQA reporting system that compares data from eight organizations, ensuring a thorough and uniform assessment.
- The CESR DCC has created tools for data managers to self-assess data quality, summarize findings, and facilitate knowledge sharing, making their model beneficial for other networks aiming to enhance data quality.
Electronic clinical laboratory test results data tables: lessons from Mini-Sentinel.
Pharmacoepidemiol Drug Saf
June 2014
Purpose: Developing electronic clinical data into a common data model posed substantial challenges unique from those encountered with administrative data. We present here the design, implementation, and use of the Mini-Sentinel Distributed Database laboratory results table (LRT).
Methods: We developed the LRT and guided Mini-Sentinel data partners (DPs) in populating it from their source data.
Managing personal health information in distributed research network environments.
BMC Med Inform Decis Mak
October 2013
Background: Studying rare outcomes, new interventions and diverse populations often requires collaborations across multiple health research partners. However, transferring healthcare research data from one institution to another can increase the risk of data privacy and security breaches.
Methods: A working group of multi-site research programmers evaluated the need for tools to support data security and data privacy.
The positive predictive value of a hyperkalemia diagnosis in automated health care data.
Pharmacoepidemiol Drug Saf
November 2010
Purpose: Our objectives were to determine performance of coded hyperkalemia diagnosis at identifying (1) clinically evident hyperkalemia and (2) serum potassium>6 mmol/L.
Methods: This retrospective observational study included 8722 patients with diabetes within an integrated healthcare system who newly initiated an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, or spironolactone. The primary outcome was first hyperkalemia-associated event (hospitalization, emergency department visit or death within 24 hours of coded diagnosis and/or potassium≥6 mmol/L) during the first year of therapy.
Background: Renin-angiotensin-aldosterone system (RAAS) inhibitors are associated with hyperkalemia, but there is little evidence demonstrating patients who receive potassium monitoring have a lower rate of hyperkalemia.
Objective: To evaluate the association between potassium monitoring and serious hyperkalemia-associated adverse outcomes among patients with diabetes newly initiating RAAS inhibitor therapy.
Design: Retrospective observational study.
Purpose: To determine the incidence of hyperkalemia-associated adverse outcomes among ambulatory patients with diabetes newly initiating renin-angiotensin-aldosterone system (RAAS) inhibitor therapy and to examine to what extent increasingly restrictive definitions of hyperkalemia-associated outcomes influenced incidence estimates.
Methods: Retrospective cohort study of 27 355 individuals with diabetes who were new users of RAAS inhibitors at three integrated healthcare systems.
Results: Using the least restrictive definition of hyperkalemia-associated outcome, an ambulatory visit (AV), inpatient hospitalization (IP), or emergency department (ED) visit co-occurring within 7 days of coded hyperkalemia diagnosis and/or potassium concentration of > or =5.